BLACKMORES (BKL) has taken full ownership of the Catalent Australia manufacturing facility in Braeside, Victoria, on Fri, following the completion of a $43.2 million acquisition (PD 26 Apr 2018).
The Australian Securities Exchange-listed supplement brand finalised the deal with a final payment of $33 million, with $20 million capital payment to be made early next year attributable to upgrades and expansions at the 30,000m2 plant.
From Mon the Braeside facility will provide close to 50% of all BKL's tablet and capsule requirements.
Further plans for the business will be raised at BKL's annual general meeting later this week.
The above article was sent to subscribers in Pharmacy Daily's issue from 29 Oct 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Oct 19
